EUVIMEDEUVIMED entdecken
Crossref

Relative Bioavailability of Dordaviprone (ONC201) is Not Affected by Co‐Administration of the Proton‐Pump Inhibitor Rabeprazole

Shamia L Faison, Joelle Batonga, Thangam Arumugham, Angela Bartkus, Marion Morrison iD, Mark J Mullin, Tim Tippin, Odin Naderer

The Journal of Clinical Pharmacology · 2025

DOI: 10.1002/jcph.6163 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Shamia L Faison und 7 weiteren Autor:innen. Beteiligte Einrichtung: Certara Strategic Consulting, Princeton, NJ, USA. Hauptthemen laut MEDLINE: Rabeprazole, Proton Pump Inhibitors, Antineoplastic Agents, Pyridones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Chimerix.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dordaviprone (ONC201) is a novel, orally administered, anti‐cancer, small molecule imipridone with demonstrated antitumor effects in patients with glioma. Dordaviprone in vitro solubility is significantly reduced at pH >4.5. Concomitant use of acid reducing agents (ARAs) may therefore impact dordaviprone solubility and bioavailability. This open‐label, single‐sequence, three‐period crossover study evaluated the effect of proton‐pump inhibitor rabeprazole on dordaviprone pharmacokinetics (PK). Periods were consecutive and comprised of period 1 (days 1‐3), period 2 (days 4‐9), and period 3 (days 10‐13). In period 1, participants received a single oral 625 mg dose of dordaviprone on day 1. In period 2, participants received six consecutive days of QD 20 mg rabeprazole alone. In period 3, patients received one oral dose of 20 mg rabeprazole (the seventh consecutive daily dose), followed 2 h later by a single 625 mg dordaviprone oral dose. PK blood samples were collected and analyzed from pre‐dose 72 h following dordaviprone administration in periods 1 and 3. Dordaviprone exposure PK parameters were similar following administration of dordaviprone alone or with rabeprazole. Geometric mean ratios and 90% CIs for dordaviprone exposure parameters with and without rabeprazole following dordaviprone administration fell within bioequivalence limits of 80.00%‐125.00% for Cmax (97.19% [86.43‐109.28]), AUClast (102.21% [95.19‐109.75]), and AUCinf (102.27% [95.21‐109.86]), indicating no effect of multiple oral doses of rabeprazole on dordaviprone relative bioavailability. Six of the 16 participants reported treatment‐emergent adverse events (TEAEs); dordaviprone‐related TEAEs were reported by three participants and were limited to mild nausea and dizziness. No dordaviprone dose adjustment or ARA treatment modification is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RabeprazoleProton Pump InhibitorsAntineoplastic AgentsPyridonesHumansMaleFemaleBiological AvailabilityCross-Over StudiesMiddle AgedAdultDrug InteractionsYoung AdultArea Under CurveAgedAdministration, Oral

Stichwörter der Autor:innen

ONC201dordavipronedrug–drug interactionpH‐dependent solubilityproton‐pump inhibitorrelative bioavailability

Substanzen

RabeprazoleProton Pump InhibitorsAntineoplastic AgentsPyridones

Autor:innen und Institutionen

  • Certara Strategic Consulting, Princeton, NJ, USA.
  • Thangam Arumugham PhD, LLC, Cary, NC, USA.
  • Chimerix Inc., Durham, NC, USA.

ORCID-Profile: Marion Morrison

Förderung

  • Chimerix

Zitieren

APA

Faison, S. L., Batonga, J., Arumugham, T., Bartkus, A., Morrison, M., Mullin, M. J., Tippin, T., & Naderer, O. (2025). Relative Bioavailability of Dordaviprone (ONC201) is Not Affected by Co‐Administration of the Proton‐Pump Inhibitor Rabeprazole. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.6163

Vancouver

Faison SL, Batonga J, Arumugham T, Bartkus A, Morrison M, Mullin MJ, et al. Relative Bioavailability of Dordaviprone (ONC201) is Not Affected by Co‐Administration of the Proton‐Pump Inhibitor Rabeprazole. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.6163

BibTeX
@article{Faison2025,
  author = {Faison, Shamia L and Batonga, Joelle and Arumugham, Thangam and Bartkus, Angela and Morrison, Marion and Mullin, Mark J and Tippin, Tim and Naderer, Odin},
  title = {Relative Bioavailability of Dordaviprone (ONC201) is Not Affected by Co‐Administration of the Proton‐Pump Inhibitor Rabeprazole},
  journal = {The Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/jcph.6163}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche